Why Is Cancer Firm Panbela Therapeutics Stock Trading Higher Today?

Panbela Therapeutics Inc PBLA shares are trading higher after the company announced the publication of preclinical and clinical data from studies of CPP-1X (also known as α-Difluoromethylornithine (DFMO) or Eflornithine) in recent-onset type 1 diabetes (T1D). 

Data published in the journal Cell Reports Medicine investigated the mechanism of polyamines and polyamine inhibition by CPP-1X on β cell stress that plays a role in the onset of type 1 diabetes in in vitro and ex vivo models. 

Results showed that DFMO treatment may preserve β cell function, reflected by C-peptide levels in patients with T1D through the modulation of urinary polyamines, particularly putrescine. 

From the Phase 1 dose range finding study of CPP-1X in patients with recent onset T1D, CPP-1X was well tolerated, and a dose-dependent inhibition of ODC was observed. 

An exploratory secondary analysis showed that at the two highest dose levels, treatment with CPP-1X stabilized C-peptide areas under the curve compared to placebo. 

When assessing immune cell populations, there were no differences between the placebo and CPP-1X patients.

Results from these studies suggest that CPP-1X is a safe, oral treatment option that may improve β cell function and/or survival in recent onset T1D.

Price Action: PBLA shares are up 31.80% at $1.05 on the last check Thursday.